1. Scrip
  2. >>Focus On Asia

Emerging Markets Earnings Roundup: Roche, Johnson & Johnson, Abbott (Part 1)

 
• By Tamra Sami

Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.

Emerging markets were a mixed picture for Big Pharma in the third quarter, with China still the clear leader but overall key markets continued to see slower growth, which many blamed on the slowdown in the West. Tenders will continue to bring increased volatility in emerging markets, and as Roche saw this quarter in Brazil, can substantially affect earnings from quarter to quarter. Meanwhile, both Johnson & Johnson and Abbott Laboratories Inc. saw their diversified strategies pay off in emerging markets, particularly with established products and devices and diagnostics.

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.